Annexon (ANNX) KOL event summary

Introduction and agenda

• Investor Day focused on vonoprument/vonaprument for geographic atrophy (GA), covering scientific, clinical, and market perspectives, company mission, disease mechanism, trial data, and strategic outlook.

• Presentations from management, executive leadership, and leading KOLs, followed by a roundtable and audience Q&A.

• Agenda included company background, mechanism of action, clinical data, and phase III program update.

KOL background and credentials

• Panel included Dr. Nora Lad (Vice Chair of Ophthalmology Clinical Research at Duke), Dr. Charles Wykoff (Chair of Clinical Trials at Retina Consultants of America), Dr. Lloyd Clark (SVP of Ophthalmology), and executive leadership.

Market insights and analysis

• GA affects over 8 million globally, with 1.5 million in the U.S.; incidence rising due to aging populations.

• Current therapies slow lesion growth but lack proven vision preservation; patients are highly motivated for effective treatments.

• Market opportunity considered blockbuster, with vision-preserving therapies potentially exceeding $7B in global peak sales.